[go: up one dir, main page]

Dermatomyositis

"Dermatomyositis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)


expand / collapse Publications
This graph shows the total number of publications written about "Dermatomyositis" by people in this website by year, and whether "Dermatomyositis" was a major or minor topic of these publications.
Below are the most recent publications written about "Dermatomyositis" by people in Profiles.
  1. The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ): A Measure to Assess the Patient Experience of Dermatomyositis Symptoms. J Rheumatol. 2024 Dec 01; 51(12):1198-1207.
    View in: PubMed
  2. Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis. Arthritis Care Res (Hoboken). 2024 Nov; 76(11):1532-1539.
    View in: PubMed
  3. Increased vascular deposition of oxidized LDL in untreated juvenile dermatomyositis. Pediatr Rheumatol Online J. 2024 Aug 08; 22(1):73.
    View in: PubMed
  4. Coordinated immune dysregulation in juvenile dermatomyositis revealed by single-cell genomics. JCI Insight. 2024 May 14; 9(12).
    View in: PubMed
  5. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). EBioMedicine. 2024 Jun; 104:105136.
    View in: PubMed
  6. Unique characteristics of anti-MDA-5 associated dermatomyositis in Southern California with a large Hispanic population. Semin Arthritis Rheum. 2024 Jun; 66:152434.
    View in: PubMed
  7. Myositis-Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality. Arthritis Rheumatol. 2024 Jun; 76(6):963-972.
    View in: PubMed
  8. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 01 17; 26(1):27.
    View in: PubMed
  9. Artificial intelligence for nailfold capillaroscopy analyses - a proof of concept application in juvenile dermatomyositis. Pediatr Res. 2024 Mar; 95(4):981-987.
    View in: PubMed
  10. The Type I Interferon Signature Reflects Multiple Phenotypic and Activity Measures in Dermatomyositis. Arthritis Rheumatol. 2023 10; 75(10):1842-1849.
    View in: PubMed